Total Payments
$36,925
2024 Payments
$694.39
Companies
46
Transactions
627
Medicare Patients
3,748
Medicare Billing
$580,160
Payment Breakdown by Category
Other$24,144 (65.4%)
Food & Beverage$10,032 (27.2%)
Travel$1,700 (4.6%)
Consulting$750.00 (2.0%)
Education$299.57 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $24,144 | 13 | 65.4% |
| Food and Beverage | $10,032 | 594 | 27.2% |
| Travel and Lodging | $1,700 | 8 | 4.6% |
| Consulting Fee | $750.00 | 2 | 2.0% |
| Education | $299.57 | 10 | 0.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $27,396 | 80 | $0 (2021) |
| LivaNova USA, Inc. | $1,166 | 21 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $919.08 | 64 | $0 (2024) |
| Biogen, Inc. | $843.42 | 60 | $0 (2019) |
| Teva Pharmaceuticals USA, Inc. | $735.16 | 49 | $0 (2019) |
| ARGENX US, INC. | $615.19 | 13 | $0 (2024) |
| Avanir Pharmaceuticals, Inc. | $536.86 | 42 | $0 (2019) |
| Sunovion Pharmaceuticals Inc. | $469.90 | 37 | $0 (2019) |
| Lundbeck LLC | $394.12 | 23 | $0 (2024) |
| ACADIA Pharmaceuticals Inc | $374.92 | 32 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $694.39 | 24 | ARGENX US, INC. ($319.49) |
| 2023 | $353.31 | 8 | ARGENX US, INC. ($261.14) |
| 2022 | $151.11 | 2 | SK Life Science, Inc. ($116.55) |
| 2021 | $1,750 | 1 | Allergan, Inc. ($1,750) |
| 2020 | $15,238 | 19 | Allergan, Inc. ($15,238) |
| 2019 | $1,763 | 108 | Novartis Pharmaceuticals Corporation ($267.32) |
| 2018 | $6,850 | 220 | Allergan Inc. ($3,027) |
| 2017 | $10,126 | 245 | Allergan Inc. ($7,299) |
All Payment Transactions
627 individual payment records from CMS Open Payments — Page 2 of 26
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/07/2023 | ARGENX US, INC. | VYVGART (Drug) | Food and Beverage | In-kind items and services | $31.72 | General |
| Category: Immunology | ||||||
| 11/02/2023 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $28.73 | General |
| Category: Neurology | ||||||
| 10/25/2023 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $26.48 | General |
| Category: NEUROLOGY | ||||||
| 09/28/2023 | Abbott Laboratories | INFINITY (Device) | Food and Beverage | In-kind items and services | $15.37 | General |
| Category: Neuromodulation | ||||||
| 09/21/2023 | ARGENX US, INC. | VYVGART (Drug) | Food and Beverage | In-kind items and services | $95.63 | General |
| Category: Immunology | ||||||
| 08/21/2023 | ARGENX US, INC. | VYVGART (Drug) | Food and Beverage | In-kind items and services | $34.41 | General |
| Category: Immunology | ||||||
| 02/16/2023 | ARGENX US, INC. | VYVGART (Drug) | Food and Beverage | In-kind items and services | $99.38 | General |
| Category: Immunology | ||||||
| 10/25/2022 | ARGENX US, INC. | VYVGART (Drug) | Food and Beverage | In-kind items and services | $34.56 | General |
| Category: Immunology | ||||||
| 06/07/2022 | SK Life Science, Inc. | XCOPRI (Drug) | Food and Beverage | In-kind items and services | $116.55 | General |
| Category: Neurology | ||||||
| 01/08/2021 | Allergan, Inc. | UBRELVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,750.00 | General |
| Category: NEUROSCIENCE | ||||||
| 05/11/2020 | Allergan, Inc. | UBRELVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $400.00 | General |
| Category: NEUROSCIENCE | ||||||
| 02/20/2020 | Allergan, Inc. | UBRELVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,920.00 | General |
| Category: NEUROSCIENCE | ||||||
| 02/20/2020 | Allergan, Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $13.64 | General |
| Category: NEUROSCIENCE | ||||||
| 02/18/2020 | Allergan, Inc. | UBRELVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,920.00 | General |
| Category: NEUROSCIENCE | ||||||
| 02/18/2020 | Allergan, Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $14.29 | General |
| Category: NEUROSCIENCE | ||||||
| 02/13/2020 | Allergan, Inc. | UBRELVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,920.00 | General |
| Category: NEUROSCIENCE | ||||||
| 02/13/2020 | Allergan, Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $11.28 | General |
| Category: NEUROSCIENCE | ||||||
| 02/11/2020 | Allergan, Inc. | UBRELVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,920.00 | General |
| Category: NEUROSCIENCE | ||||||
| 02/11/2020 | Allergan, Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $18.32 | General |
| Category: NEUROSCIENCE | ||||||
| 01/30/2020 | Allergan, Inc. | UBRELVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,400.00 | General |
| Category: NEUROSCIENCE | ||||||
| 01/30/2020 | Allergan, Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $94.48 | General |
| Category: NEUROSCIENCE | ||||||
| 01/22/2020 | Allergan, Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $55.07 | General |
| Category: NEUROSCIENCE | ||||||
| 01/18/2020 | Allergan, Inc. | UBRELVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,500.00 | General |
| Category: NEUROSCIENCE | ||||||
| 01/18/2020 | Allergan, Inc. | UBRELVY (Drug) | Travel and Lodging | In-kind items and services | $471.68 | General |
| Category: NEUROSCIENCE | ||||||
| 01/18/2020 | Allergan, Inc. | UBRELVY (Drug) | Travel and Lodging | In-kind items and services | $253.49 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 643 | 797 | $203,987 | $71,963 |
| 2022 | 16 | 772 | 927 | $256,419 | $80,181 |
| 2021 | 18 | 858 | 16,385 | $550,234 | $164,032 |
| 2020 | 24 | 1,475 | 31,106 | $837,910 | $263,984 |
Total Patients
3,748
Total Services
49,215
Medicare Billing
$580,160
Procedure Codes
74
All Medicare Procedures & Services
74 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 141 | 144 | $74,352 | $19,276 | 25.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 91 | 178 | $46,689 | $16,253 | 34.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 82 | 98 | $10,942 | $7,345 | 67.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 86 | 102 | $8,392 | $4,803 | 57.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 43 | 44 | $15,461 | $4,427 | 28.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 41 | 41 | $7,769 | $4,307 | 55.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 25 | 25 | $5,932 | $3,669 | 61.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 21 | 50 | $9,113 | $3,203 | 35.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 27 | 28 | $5,170 | $3,012 | 58.2% |
| 95910 | Nerve conduction, 7-8 studies | Facility | 2023 | 24 | 24 | $6,410 | $1,941 | 30.3% |
| 95911 | Nerve conduction, 9-10 studies | Facility | 2023 | 14 | 14 | $4,675 | $1,447 | 31.0% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 18 | 18 | $4,669 | $947.37 | 20.3% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 12 | 12 | $2,188 | $715.66 | 32.7% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Facility | 2023 | 18 | 19 | $2,225 | $617.21 | 27.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 148 | 152 | $78,482 | $23,851 | 30.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 91 | 189 | $49,575 | $15,249 | 30.8% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 103 | 106 | $27,496 | $8,312 | 30.2% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 55 | 57 | $20,029 | $5,995 | 29.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 46 | 77 | $14,033 | $4,429 | 31.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 37 | 41 | $5,938 | $3,099 | 52.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 33 | 33 | $10,655 | $3,042 | 28.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 46 | 49 | $5,298 | $2,515 | 47.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 36 | 39 | $6,668 | $2,253 | 33.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 15 | 15 | $6,260 | $2,244 | 35.8% |
| 95910 | Nerve conduction, 7-8 studies | Facility | 2022 | 27 | 27 | $7,212 | $1,960 | 27.2% |
About Dr. Lawrence King, M.D
Dr. Lawrence King, M.D is a Neurology healthcare provider based in Pensacola, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/22/2007. The National Provider Identifier (NPI) number assigned to this provider is 1609901487.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lawrence King, M.D has received a total of $36,925 in payments from pharmaceutical and medical device companies, with $694.39 received in 2024. These payments were reported across 627 transactions from 46 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($24,144).
As a Medicare-enrolled provider, King has provided services to 3,748 Medicare beneficiaries, totaling 49,215 services with total Medicare billing of $580,160. Data is available for 4 years (2020–2023), covering 74 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Neurology
- Location Pensacola, FL
- Active Since 02/22/2007
- Last Updated 01/04/2012
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1609901487
Products in Payments
- UBRELVY (Drug) $16,988
- BOTOX CHRONIC MIGRAINE (Drug) $6,643
- BOTOX (Biological) $3,420
- VNS Therapy (Device) $1,334
- GILENYA (Drug) $579.28
- NUEDEXTA (Drug) $536.86
- APTIOM (Drug) $469.90
- TYSABRI (Biological) $404.40
- NUPLAZID (Drug) $374.92
- TECFIDERA (Drug) $346.83
- COPAXONE (Drug) $319.79
- VYVGART HYTRULO (Drug) $319.49
- VYVGART (Drug) $295.70
- AJOVY (Drug) $278.30
- GOCOVRI (Drug) $218.17
- LEMTRADA (Drug) $192.52
- ONFI (Drug) $161.68
- NAMZARIC (Drug) $156.07
- TROKENDI XR (Drug) $146.09
- AIMOVIG (Biological) $138.29
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Pensacola
David Bear, D.o, D.O
Neurology — Payments: $585,571
Neurology $585,571
Dr. Roman Kesler, Do, DO
Neurology — Payments: $69,973
Neurology $69,973
Dr. Ethan Gore, M.d, M.D
Neurology — Payments: $47,830
Neurology $47,830
Dr. Henry Porter, M.d, M.D
Neurology — Payments: $40,702
Neurology $40,702
George Dmytrenko, M.d., Ph.d, M.D., PH.D
Neurology — Payments: $33,531
Neurology $33,531
Daniel Ross, D.o, D.O
Neurology — Payments: $27,982
Neurology $27,982